T Ullrich1, M Quentin2, A K Schmaltz1, C Arsov3, C Rubbert1, D Blondin1, R Rabenalt3, P Albers3, G Antoch1, L Schimmöller1. 1. Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, D-40225, Dusseldorf, Germany. 2. Department of Diagnostic and Interventional Radiology, University Dusseldorf, Medical Faculty, D-40225, Dusseldorf, Germany. michael.quentin@gmx.de. 3. Department of Urology, University Dusseldorf, Medical Faculty, D-40225, Dusseldorf, Germany.
Abstract
OBJECTIVES: To prospectively evaluate the effect of hyoscine butylbromide (HBB) on visualisation of anatomical details and motion-related artefacts in mp-MRI of the prostate at 3.0 Tesla. METHODS: One hundred and three consecutive patients (65 ± 10 years) were included in this trial, powered to demonstrate an improvement of image quality after HBB administration, assessed on a 5-point scale by two blinded readers. All patients received high-spatial resolution axial T2-weighted TSE sequences at 3.0 T without spasmolytic agent, repeated after application of 40 mg HBB and followed by routine mp-MRI. Secondary endpoints were (1) susceptibility to side effects, (2) dependence of spasmolytic effect on patients´ weight, and (3) prostate volume. RESULTS: In 68% of patients, HBB significantly improved the anatomic score (mean 3.4 ± 0.9 before and 4.4 ± 0.7 after HBB for both readers, p = <0.001). In 67%, HBB significantly enhanced the artefact score (mean 3.2 ± 1 before and 4.2 ± 0.8 after HBB for reader 1, p = <0.001; 3.2 ± 1 and 4.1 ± 0.8 for reader 2, p = <0.001). Subgroup analysis revealed no statistically significant difference between patients with different bodyweight or prostate volume. Inter-reader agreement was excellent (k = 0.95-0.98). CONCLUSIONS: Hyoscine butylbromide significantly improves image quality and reduces motion-related artefacts in mp-MRI of the prostate independent of bodyweight or prostate volume. No side effects were reported. KEY POINTS: • Hyoscine butylbromide (HBB) improved image quality in over 2/3 of patients. • Severe artefacts were reduced after HBB in more than 20%. • The number of non-diagnostic MRI was reduced to <1% after HBB. • HBB effect was independent of bodyweight and prostate volume. • No side effects of HBB were reported in this study population.
OBJECTIVES: To prospectively evaluate the effect of hyoscine butylbromide (HBB) on visualisation of anatomical details and motion-related artefacts in mp-MRI of the prostate at 3.0 Tesla. METHODS: One hundred and three consecutive patients (65 ± 10 years) were included in this trial, powered to demonstrate an improvement of image quality after HBB administration, assessed on a 5-point scale by two blinded readers. All patients received high-spatial resolution axial T2-weighted TSE sequences at 3.0 T without spasmolytic agent, repeated after application of 40 mg HBB and followed by routine mp-MRI. Secondary endpoints were (1) susceptibility to side effects, (2) dependence of spasmolytic effect on patients´ weight, and (3) prostate volume. RESULTS: In 68% of patients, HBB significantly improved the anatomic score (mean 3.4 ± 0.9 before and 4.4 ± 0.7 after HBB for both readers, p = <0.001). In 67%, HBB significantly enhanced the artefact score (mean 3.2 ± 1 before and 4.2 ± 0.8 after HBB for reader 1, p = <0.001; 3.2 ± 1 and 4.1 ± 0.8 for reader 2, p = <0.001). Subgroup analysis revealed no statistically significant difference between patients with different bodyweight or prostate volume. Inter-reader agreement was excellent (k = 0.95-0.98). CONCLUSIONS:Hyoscine butylbromide significantly improves image quality and reduces motion-related artefacts in mp-MRI of the prostate independent of bodyweight or prostate volume. No side effects were reported. KEY POINTS: • Hyoscine butylbromide (HBB) improved image quality in over 2/3 of patients. • Severe artefacts were reduced after HBB in more than 20%. • The number of non-diagnostic MRI was reduced to <1% after HBB. • HBB effect was independent of bodyweight and prostate volume. • No side effects of HBB were reported in this study population.
Authors: Zarine K Shah; Saba N Elias; Ronney Abaza; Debra L Zynger; Lawrence A DeRenne; Michael V Knopp; Beibei Guo; Ryan Schurr; Steven B Heymsfield; Guang Jia Journal: Acad Radiol Date: 2015-01-08 Impact factor: 3.173
Authors: Ivo G Schoots; Monique J Roobol; Daan Nieboer; Chris H Bangma; Ewout W Steyerberg; M G Myriam Hunink Journal: Eur Urol Date: 2014-12-03 Impact factor: 20.096
Authors: Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton Journal: Lancet Date: 2017-01-20 Impact factor: 79.321
Authors: Pieter J L De Visschere; Alberto Briganti; Jurgen J Fütterer; Pirus Ghadjar; Hendrik Isbarn; Christophe Massard; Piet Ost; Prasanna Sooriakumaran; Cristian I Surcel; Massimo Valerio; Roderick C N van den Bergh; Guillaume Ploussard; Gianluca Giannarini; Geert M Villeirs Journal: Insights Imaging Date: 2016-02-04
Authors: Cynthia Schmidt; Andreas M Hötker; Urs J Muehlematter; Irene A Burger; Olivio F Donati; Borna K Barth Journal: Abdom Radiol (NY) Date: 2021-03-26
Authors: Finbar Slevin; Matthew Beasley; Jim Zhong; Eleanor Hudson; Richard Speight; John Lilley; Louise J Murray; Ann M Henry Journal: BJR Open Date: 2021-07-29
Authors: Mehmet Coskun; Sherif Mehralivand; Joanna H Shih; Maria J Merino; Bradford J Wood; Peter A Pinto; Tristan Barrett; Peter L Choyke; Baris Turkbey Journal: Abdom Radiol (NY) Date: 2020-12
Authors: T Ullrich; M D Kohli; M A Ohliger; K Magudia; S S Arora; T Barrett; L K Bittencourt; D J Margolis; L Schimmöller; B Turkbey; A C Westphalen Journal: Abdom Radiol (NY) Date: 2020-07-21
Authors: Francesco Giganti; Veeru Kasivisvanathan; Alex Kirkham; Shonit Punwani; Mark Emberton; Caroline M Moore; Clare Allen Journal: Br J Radiol Date: 2021-07-08 Impact factor: 3.039